skip to Main Content

Our Science

References

  1. Dreier, et al. (2002), Int. J. Cancer, 100: 690–697
  2. Srivastava & Riddell (2018), J Immunol, 200 (2) 459-468
  3. Klinger, et al. (2012), Blood, 119:6226-6233
  4. American Cancer Society, 2019
  5. Amgen. (2014). Blincyto: Highlights of prescribing information. Thousand Oaks, CA: Author
  6. Bristol-Myers Squibb Company. (2011). Yervoy: Highlights of prescribing information. Princeton, NJ: Author
  7. Bristol-Myers Squibb Company. (2018). Opdivo: Highlights of prescribing information. Princeton, NJ: Author
  8. Kite Pharma, Inc. (2017). Yescarta: Highlights of prescribing information. Santa Monica, CA: Author
  9. Merck Sharp & Dohme Corp. (2014). Keytruda: Highlights of prescribing information. Whitehouse Station, NJ: Author
  10. Novartis. (2017). Kymriah: Highlights of prescribing information. East Hanover, NJ: Author

COBRATM Therapeutic Platform

The COBRA™ platform addresses these challenges by activating T cells and initiating tumor killing only at the site of the tumor. Unlike other bispecific T cell engagers that are inherently active and potent when administered, each COBRA™ therapy is designed to bind to a specific target and engineered to be an inactive prodrug until it enters the tumor microenvironment.

COBRA™ molecules also include a component that extends their half-life in circulation prior to activation, which allows for less frequent dosing versus the patient-unfriendly continuous infusion required for first generation T cell engagers. Once activated within the tumor microenvironment, this half-life extension component is physically detached, allowing for rapid elimination of the active molecules after they’ve killed the cancer cells, further improving the safety window by reducing the chance that an activated COBRA™ molecule will travel to nearby healthy tissues and cause damage.

References

  1. Cancer Classification | SEER Training. (2019). Retrieved from https://training.seer.cancer.gov/disease/categories/classification.html
  2. Based on efficacy data in the Prescribing Information for each therapy listed: breast, lung, prostate, colorectal, melanoma, uterine & ovarian, kidney & renal, head & neck, pancreas

Pipeline

What sets us apart from our peers is our single focus on developing potent and conditionally active T cell targeted immunotherapies for solid tumor cancers with increased tumor specificity and reduced toxicity.

Our COBRA™ pipeline features proprietary and patented conditionally active T cell engaging molecules that we are rapidly accelerating toward the clinic.

Maverick Therapeutics Pipeline
Back To Top